10:45 AM EDT, 08/02/2024 (MT Newswires) -- Lexicon Pharmaceuticals ( LXRX ) filed a registration statement Friday with the US Securities and Exchange Commission for the potential sale of up to $200 million of its securities from time to time.

The filing covers common and preferred shares, debt securities, warrants, rights, and units.

Net proceeds from any such sale will be used for research, development, commercialization, and general corporate purposes, including potential acquisitions or investments, according to the filing.

Price: 1.71, Change: -0.32, Percent Change: -15.59